title: Uptake blockade of endocannabinoids in the NTS modulates baroreflex-evoked sympathoinhibition.
abstract: Previous studies supporting a possible physiological role for an endogenous cannabinoid, arachidonylethanolamide (AEA, anandamide), showed a significant increase in AEA content in the nucleus tractus solitarius (NTS) after an increase in blood pressure (BP) and prolonged baroreflex inhibition of renal sympathetic nerve activity (RSNA) after exogenous AEA microinjections into the NTS. These results, along with other studies, support the hypothesis that endogenous AEA can modulate the baroreflex through cannabinoid CB(1) receptor activation within the NTS. This study was performed to characterize the physiological role of endogenously released cannabinoids (endocannabinoids) in regulating baroreflex control of RSNA through actions in the NTS. Endocannabinoid effects were assessed by measuring the RSNA baroreflex response to increased pressure after bilateral microinjections of AM404, an endocannabinoid transport inhibitor, into the NTS of adult male Sprague Dawley rats. AM404 blocks uptake of endocannabinoids and enhances the effects of any endocannabinoids released [M. Beltramo, et al., Functional role of high-affinity anandamide transport, as revealed by selective inhibition, Science 277 (5329) (1997) 1094-1097.] into the NTS. Therefore, it was hypothesized that microinjections of AM404 should exhibit effects similar to microinjections of exogenous AEA. In this study, AM404 microinjections into the NTS were found to significantly prolong baroreflex inhibition of RSNA compared to control, similar to effects of exogenous AEA. This effect is thought to result from an increased endocannabinoid presence in the NTS, leading to prolonged CB(1) receptor activation. These results indicate that endocannabinoids released in the NTS have the potential to modulate baroreflex control at this site in the central baroreflex pathway.
authors.affiliation: Zablocki Department of Veterans Affairs Medical Center, Medical College of Wisconsin, Milwaukee, 53295, USA.
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Brozoski
authors.forename: Caron
authors.initials: C
authors.lastname: Dean
authors.forename: Francis A
authors.initials: FA
authors.lastname: Hopp
authors.forename: Jeanne L
authors.initials: JL
authors.lastname: Seagard
mesh_terms: D000818:Animals; D001095:Arachidonic Acids / Q000008:administration & dosage; D017704:Baroreflex / Q000187:drug effects / Q000502:physiology*; D001692:Biological Transport / Q000187:drug effects; D001794:Blood Pressure; D063385:Cannabinoid Receptor Modulators / Q000378:metabolism*; D063388:Endocannabinoids; D007668:Kidney / Q000294:innervation; D008297:Male; D008845:Microinjections; D009433:Neural Inhibition / Q000187:drug effects*; D009434:Neural Pathways / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017552:Solitary Nucleus / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D013564:Sympathetic Nervous System / Q000187:drug effects* / Q000502:physiology
chemical_list: D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; C107594:N-(4-hydroxyphenyl)arachidonylamide